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Abstract
MECP2 mutations cause Rett syndrome (RTT), a severe and
progressive neurodevelopmental disorder mainly affecting
females. Although RTT patients exhibit delayed onset of symp-
toms, several evidences demonstrate that MeCP2 deficiency
alters early development of the brain. Indeed, during early
maturation, Mecp2 null cortical neurons display widespread tran-
scriptional changes, reduced activity, and defective morphology.
It has been proposed that during brain development these
elements are linked in a feed-forward cycle where neuronal
activity drives transcriptional and morphological changes that
further increase network maturity. We hypothesized that the
enhancement of neuronal activity during early maturation might
prevent the onset of RTT-typical molecular and cellular pheno-
types. Accordingly, we show that the enhancement of excitabil-
ity, obtained by adding to neuronal cultures Ampakine CX546,
rescues transcription of several genes, neuronal morphology, and
responsiveness to stimuli. Greater effects are achieved in
response to earlier treatments. In vivo, short and early adminis-
tration of CX546 to Mecp2 null mice prolongs lifespan, delays
the disease progression, and rescues motor abilities and spatial
memory, thus confirming the value for RTT of an early restora-
tion of neuronal activity.
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Introduction
Mutations in the X-linked methyl-CpG-binding protein 2 (MECP2)
gene are associated with a number of neurological conditions among
which the most frequent is Rett syndrome (RTT; Amir et al, 1999).
RTT is the most common cause of severe intellectual disability in
females, as it affects one female every 10,000 born alive (Chahrour &
Zoghbi, 2007). Given the high levels of MeCP2 in the brain, the
neurological features of RTT are by far the most thoroughly
described. Small brain size and reduced weight, thin corpus callo-
sum, and diminished cortical thickness are typical of the pathology
(Armstrong et al, 2001; Carter et al, 2008; Belichenko et al, 2009).
HemizygousMecp2 null male mice recapitulate much of these defects
in adult stages, therefore proving their face validity. However,
diversely from most RTT girls, they feature significantly reduced life
span. Defective neuronal features have also been reported in the RTT
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mouse models, including reduced soma size, dendritic branching,
number of spines, and synaptic contacts (Guy et al, 2001; Kishi &
Macklis, 2004; Fukuda et al, 2005; Chao et al, 2007; Belichenko et al,
2009; Baj et al, 2014; Rietveld et al, 2015; Bedogni et al, 2016;
Sampathkumar et al, 2016). Importantly, although these phenotypes
vary depending on the cell type, the age and type of Mecp2 muta-
tions, soma size is consistently reduced throughout development of
mouse models of Rett syndrome, therefore appearing as a robust and
reliable biomarker (Wang et al, 2013).
Besides morphological alterations, impaired neuronal functions
were also observed in adult mice, resulting in a complex derangement
of brain activity (Nelson & Valakh, 2015).Mecp2 null cortical neurons
feature reduced activity caused by both a selective impairment in exci-
tatory transmission and a reduced connectivity between excitatory
neurons (Dani et al, 2005; Dani & Nelson, 2009; Shepherd & Katz,
2011; Sceniak et al, 2016). Mecp2 KO visual cortex manifest similar
deficiency in neuronal and network activity that, however, appears to
result from stronger inhibition (Durand et al, 2012). On the contrary,
the adult and symptomaticMecp2 null hippocampus (but not the pre-
symptomatic one) suffers from elevated neuronal activity and
occluded LTP caused by potentiated synapses (Li et al, 2017).
The outbreak of symptoms typically follows an apparently
normal developmental phase that lasts 6–18 months in humans
(Cosentino et al, 2019) and roughly 40 days in Mecp2 null animals
(Guy et al, 2001; Chen et al, 2001). However, subtle symptoms in
RTT girls have been described even before the onset of the overt
phase of the pathology (Fehr et al, 2011; Dolce et al, 2013; Marschik
et al, 2013; Cosentino et al, 2019). Similarly, animal models display
defects already during embryonic development (Bedogni et al, 2016;
Cobolli Gigli et al, 2018; Mellios et al, 2018) or immediately after
birth (Dani et al, 2005; Picker et al, 2006; Chao et al, 2007). Such
evidence proves that the lack of MeCP2 affects early development of
the mammalian brain although the phenotypic consequences of it
become overt later on (Ip et al, 2018; Cosentino et al, 2019).
In line with the role of Mecp2 as master regulator of transcription
(Skene et al, 2010; Lagger et al, 2017; Shah & Bird, 2017), gene
expression is affected in null samples already during early develop-
ment both in vivo (Cobolli Gigli et al, 2018) and in vitro (Mellios
et al, 2018), as well as neuronal morphology and responsiveness to
external stimuli (Bedogni et al, 2016). We thus hypothesized that
these early developmental defects could be a key element to explain
the thoroughly described poor maturity of adult Mecp2-deficient
neuronal networks. Indeed, while neuronal activity is surely
involved in the maintenance of mature synaptic structures (Greer &
Greenberg, 2008; Flavell & Greenberg, 2008), early patterns of spon-
taneous activity have been reported already during embryonic and
early postnatal cortical development (Corlew et al, 2004; Platel et al,
2005; Spitzer, 2006). However, such spontaneous activity cannot be
simply considered a measure of the gradually increasing maturation
of membrane excitability, as it also drives neurodevelopmental
processes that include refinement of neuronal identity and newborn
neurons migration, survival, and connectivity (Weissman et al,
2004; Bonetti & Surace, 2010; Yamamoto & Lopez-Bendito, 2012;
Luhmann et al, 2015). Indeed, it has been proposed that neuronal
activity is required at all developmental stages, as it refines signaling
via gene expression, providing checkpoints to validate or modulate
genetic programs essential for the establishment of proper neuronal
maturity (Spitzer, 2006). We thus tested the possible causative link
between poor maturity and reduced neuronal activity in null
samples by pharmacologically stimulating null neurons within early
time windows. To focus on the earliest steps of neuronal matura-
tion, we used neurons differentiated from cortical neuroprecursors
(NPCs), which recapitulate the in vivo process of neuronal differen-
tiation and the subsequent steps of gliogenesis (Paridaen & Huttner,
2014). Functional in vitro assessments were produced using dif-
ferentiated neurons or primary neuronal cultures. Eventually, we
validated our results in vivo using Mecp2 null animals.
Our in vitro data demonstrate that the enhancement of activity
rescues Mecp2 null neurons morphology and expression of selected
transcripts, thus restoring impaired network functions. Accordingly,
we show that the exposure of Mecp2 null animals to Ampakine
CX546 within an early and short postnatal time window prolonged
life span and ameliorated their behavioral scoring. Importantly, both
in vivo and in vitro rescue effects lasted long after the exposure to
the drug, implying the long persistence of such effects. Our results
suggest that the enhancement of neuronal activity in Mecp2 null
neurons sets in place plasticity mechanisms that mitigate maturation
defects likely through the modulation of a feed-forward cycle
(Spitzer, 2006). We suggest that the time frame in which such mech-
anisms occur highlights an important early molecular phase of the
pathology, during which null neurons are affected by a number of
transcriptional impairments that are prodromal of the subsequent
onset of overt symptoms. Therapeutic strategies acting within this
early molecular phase might be more effective in readdressing the
pathological trajectory of null neurons development toward more
physiological directions than later treatments.
Results
Lack of Mecp2 does not affect the early commitment of cultured
cortical NPCs
To focus on early mechanisms of maturation of Mecp2 null neuronal
networks, we collected neuroprecursor cells (NPCs) from E15 cere-
bral cortex and induced their in vitro differentiation as previously
described (Magri et al, 2011; Cobolli Gigli et al, 2018). Being
synchronously generated, the stage of differentiation of such popu-
lations is roughly comparable. Defects masked in heterogeneous
populations are consequently easier to detect, an advantage in the
case of Mecp2 studies, where in most cases defects are very subtle
(Bedogni et al, 2014). Moreover, this model enables to reduce the
use of mice and is suitable for pharmacological manipulations
(Gorba & Conti, 2013).
NPCs spontaneously proliferate in a self-renewing manner in the
presence of the mitogens EGF and FGF2 (Gritti et al, 1999), while the
presence of fetal bovine serum drives their differentiation into the
three main cellular populations of the brain: neurons, astrocytes,
and oligodendrocytes (Magri et al, 2011; Fig 1A). We measured the
distinct cellular populations at different developmental stages of
NPCs differentiation by immunostaining wild-type (wt) and Mecp2
null cultures for Tuj1, Gfap, and Olig2. We found that the lack of
Mecp2 did not affect the percentage of neurons, astrocytes, and
oligodendrocytes at any differentiation stage (Fig 1B–J), in line with
previous observations (Kishi & Macklis, 2004). In particular, neurons
contributed for a percentage of roughly 27.2  1.1 and 22.2  0.6 at
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DIV8 and 21.6  1.08 and 19.7  1.6 at DIV22 in wt and null
samples, respectively (two-way ANOVA followed by Bonferroni post
hoc test; Fig 1D). The percentage of Gfap positive cells increased
from 35.7  0.8 and 39.4  1.06 at DIV8 to 69.8  4.7 and
69.4  4.4 at DIV22 in wt and null samples, respectively (Fig 1G).
Gfap-positive cells were, therefore, generated at a later time point
than neurons, in line with the in vivo dynamics of glial cells genesis
and differentiation (Paridaen & Huttner, 2014). The percentage of
oligodendrocytes (roughly 7% in both genotypes) remained equal
throughout differentiation (two-way ANOVA followed by Bonferroni
post hoc test; Fig 1J). At DIV8, we found that although some cells
expressed Map2, a typical marker of mature neurons (Fig EV1A),
roughly 85% of wt and null cells were positive for Nestin
(Fig EV1C), thus suggesting that immature NPCs were still present at
that stage. Such population eventually disappeared at DIV22
(Fig EV1B), in line with the decreasing expression of the cell cycle
marker Ki67 over time (*P < 0.05, **P < 0.01, ****P < 0.0001, two-
way ANOVA followed by Bonferroni post hoc test; Fig EV1D). We
conclude that at DIV22 most cells terminally differentiated into their
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To further support these findings, we repeated the analysis on NPCs
derived from heterozygous Mecp2/+ female cerebral cortices, which
are generally subjected to random X chromosome inactivation
(Fig EV1E–H). Consistent with our previous results (Fig 1D and G),
at DIV22 we found no different percentage of either neurons (Tuj1+;
47.8  1.4 and 52.2  1.4) or glial cells (Gfap+; 48.9  1.5 and
51.1  1.5) between the Mecp2-positive and Mecp2-negative popu-
lations (Student’s t-test; Fig EV1F–H).
Lack of Mecp2 affects transcription of in vitro
differentiated NPCs
To verify whether our model recapitulated the typical delay in
neuronal maturation (Bedogni et al, 2016; Mellios et al, 2018; Cobolli
Gigli et al, 2018), we exploited the expression levels of Neun, a
neuronal-specific marker that increases with maturation at a slower
rate compared to Tuj1 (Menezes & Luskin, 1994; Walker et al, 2007).
We analyzed null and wt cultures at DIV14 (Fig 1K–O) and found
that the number of Neun and Tuj1 positive cells overlapped between
wt and null samples (Neun: 3.2  0.4 and 2.5  0.3 in wt and null
respectively; Tuj1: 17.9  0.4 and 17.8  1.8 in wt and null, respec-
tively; two-way ANOVA followed by Bonferroni post hoc test;
Fig 1L). However, the intensity of the Neun signal was significantly
decreased in null samples (5190  85.5 in wt and 4855  39.98 in
null samples; **P < 0.01, Student’s t-test; Fig 1M), as well as the
percentage of null cells expressing low levels of it (**P < 0.01,
Kolmogorov–Smirnov test; Fig 1N and n0).
Moreover, in wt cultures the mRNA levels of Neun increased
with time, while the expression of Neun did not change in Mecp2
null cultures between DIV3 and DIV14 (****P < 0.0001, two-way
ANOVA followed by Bonferroni post hoc test; Figs 1O and EV2). To
corroborate the existence of transcriptional differences among the
two experimental groups, we measured the expression of two sets
of genes that included either 16 mRNAs typically expressed by NPCs
or 51 transcripts mainly expressed by post-mitotic neurons
(Appendix Table S1). In line with previous studies (Cobolli Gigli
et al, 2018), at the earliest time point (DIV3), changes were mainly
observed in transcripts selected for their expression in mitotic or
early post-mitotic neurons, such as the increased expression of
Neurod1 (Fig 1P). At DIV14 we found reduced levels of transcripts
involved in the responsiveness to external stimuli (such as ionic
channel subunits, Glutamate and GABA receptors) and in broader
neuronal functions (Syn1, Psd95) (*P < 0.05, **P < 0.01,
***P < 0.001, ****P < 0.0001; two-way ANOVA followed by Sidak
multiple comparison test; Fig 1P). These results were recapitulated
by principal component analyses (PCA) used to qualitatively visual-
ize the segregation of the two genotypes based on the differential
expression of markers of either progenitor or mature post-mitotic
cells. In fact, by applying a set of genes defining immature neurons
we unmasked at DIV0 a segregation (Fig EV2A–A0) that disappeared
at later time points. Conversely, the use of markers of post-mitotic
neurons showed a more evident separation at DIV14 (Fig EV2B–B0).
Notably, the deregulation of several genes was also evident at
DIV21 (*P < 0.05, **P < 0.01, ***P < 0.001; two-way ANOVA
followed by Bonferroni post hoc test; Fig EV2C), thus confirming
that NPC-derived Mecp2 null neurons well recapitulate the early
onset and persistency of transcriptional changes due to the lack of
Mecp2 (Bedogni et al, 2016; Cobolli Gigli et al, 2018).
The in vitro established Mecp2 null neuronal networks are
functionally and morphologically immature
To verify the impact of maturation defects on the activity of Mecp2
null neuronal networks, we next focused on functional assessments.
We plated dissociated NPCs at high density (8,000 cells/µl) on
multi-electrode array (MEA) chips to record spontaneous electrical
activity (Fig 2A and B). The same population of cells was recorded
at two time points (DIV18 and 22) to monitor the functional devel-
opment of cell-to-cell communication and the generation of an
active network over time.
The spontaneous activity of the developing networks was
assessed through five parameters: number of active electrodes,
◀ Figure 1. Lack of Mecp2 does not affect the commitment of NPCs but delays their differentiation.
A Schematic representation of the differentiation protocol and the cell types composing cultures differentiated from NPCs (adapted from Carlessi et al, 2013).
B–J Representative immunofluorescences of the cell types composing the wt and Mecp2 null cultures differentiated from NPCs. Antibodies against Tuj1, Gfap, and
Olig2 were used to recognize neurons, astrocytes, and oligodendrocytes. In D, G, and J, the percentage of cells positive (mean  SEM) for each marker was
counted over the total of DAPI-positive cells (100%). No difference between genotypes was highlighted (two-way ANOVA); the variation through time resulted
significant for the levels of Tuj1 and Gfap (two-way ANOVA: F(1, 16) = 9.542, P-value < 0.05 and F(1, 10) = 68.95, P-value < 0.0001, respectively). Sample size:
n ≥ 3 wells obtained from two independent preparations; for each well, 10 random fields were acquired. Scale bars: 30 µm.
K Representative immunostaining of Neun (green) and Tuj1 (red)-positive neurons at DIV14. Scale bars: 15 µm.
L, M Graphs show the percentage of Neun and Tuj1-positive cells and the average Neun intensity in wt and null samples (L: mean  SEM; M: central band shows the
median, boxes show the lower and upper quartiles, whiskers show max and min values). The percentage of cells positive for each marker was counted over the
total of DAPI-positive cells. Student’s t-test highlighted a significant decrease of Neun intensity in null samples. **P-value < 0.01. Sample size: n ≥ 10 wells
obtained from two independent preparations.
N, n0 The binned distribution of Neun intensity is plotted as both frequency distribution graphs, in panel N, and cumulative probability plot in panel n’. The null
neurons distribution is significantly shifted toward low levels of Neun intensity, Kolmogorov–Smirnov test **P-value < 0.01. Each value in panel N is represented
as mean  SEM obtained by measuring 900 cells from n ≥ 10 wells derived from two different preparations.
O Neun expression levels assessed at DIV0, DIV3, and DIV14 are represented as 2-Δct. Box plots show the median (central band), the lower and upper quartiles (boxes)
and the max and min values (whiskers) from at least 5 samples obtained from two independent preparations. Two-way ANOVA indicated both a significant
genotype effect (F(2, 28) = 19.60; P < 0.0001) and time effect (F(2, 28) = 93.70; P < 0.0001). Bonferroni post hoc test revealed significant differences between
genotypes at DIV 14 but not at DIV0 and DIV 3. ****P-value < 0.0001.
P Scatter plots describing the transcriptional levels of selected differentially expressed genes in wt andMecp2 null cultures differentiated from NPCs and analyzed at DIV3
and DIV14. For each gene, two-way ANOVA and Sidak multiple comparison test were used to assess difference between genotypes at the two selected time points
(*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001). Values are represented as mean  SEM. Sample size: ≥ 5 samples obtained from two independent preparations.
Source data are available online for this figure.
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Weighted Mean Firing Rate (WMFR), frequency and duration of
spontaneous bursts, and intra-burst intervals (Fig 2C–G). The matu-
ration of wt network activity was demonstrated by the significant
increase of WMFR, burst frequency, and burst duration at DIV22
compared to DIV18 and the increasing trend in the number of active





M N O P Q
I J K
D E F G
Figure 2. Neurons derived from Mecp2 null NPCs are morphologically more immature than wt controls and establish less active networks.
A, B Wt or Mecp2 null NPCs plated on the grid of 64 MEA electrodes. Scale bars: 50 µm.
C–G Line graphs represent the changes through time of 5 parameters describing neuronal activity. Difference between genotypes and through time were analyzed
using two-way ANOVA for repeated measures and Bonferroni post hoc test; * refers to differences between genotypes (*P-value < 0.05; **P-value < 0.01;
****P-value < 0.0001); # refers to differences between the two time points (#P-value < 0.05; ##P-value < 0.01). Sample size: n = 8 wells deriving from three
independent preparations. Values are represented as mean  SEM.
H–K Raster plots (H and I) and their quantitation under basal conditions and upon 100 µM 4-AP exposure. The magnitude of the response after stimulation is
expressed either as fold change (J) or as the averaged maximal values reached after 4-AP exposure (K). Dotted line in J represents untreated controls (set to 1).
Values are represented as mean  SEM. Student’s t-test, *P-value < 0.05. Sample size n = 8 wells deriving from three independent preparations.
L Wt and null neurons counterstained with an antibody against Tuj1 and DAPI at different time points. The binary mask is representative of a neuron used to study
morphology. Scale bars: 30 µm.
M–Q Each graph represents a different morphological parameter analyzed at selected time point. Two-way ANOVA indicated both a significant time effect (F 4,
20) = 282.5 and P < 0.0001 for the number of intersections; (F 4, 26) = 104.5 and P < 0.0001 for the total dendritic length; (F 4, 20) = 58.51 and P < 0.0001 for
the maximal dendritic length; (F 3, 22) = 38.32 and P < 0.0001 for polarization) and genotype effect ((F 1, 20) = 25.1 and P < 0.0001 for the number of
intersections; (F 4, 26) = 16.0 and P = 0.005 for the total dendritic length; (F 1, 20) = 17.24 and P = 0.005 for the maximal dendritic length; (F 1, 22) = 18.76 and
P < 0.003 for polarization). Bonferroni multiple comparison test was used to assess difference between wt and null neurons at each analyzed time point. The
dotted line in panel P represents the cut-off above which a culture is defined polarized (Horton et al, 2006). Statistical significance for Q was assessed by Student’s
t-test. Values are represented as mean  SEM; *P-value < 0.05; **P-value < 0.01; ****P-value < 0.0001. Sample size: n ≥ 3 wells deriving from three independent
preparations; for each well, we measured at least 15 cells.
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Bonferroni post hoc test), in line with published observations on the
same model (de Groot et al, 2014). The lack of Mecp2 instead drove
a markedly alteration of this pattern, with null cultures showing
lack of functional maturation between DIV18 and DIV22, as indi-
cated by the analysis of active electrodes, WMFR, burst frequency,
and duration (two-way ANOVA followed by Bonferroni post hoc
test; Fig 2C–F). The intra-burst intervals showed a similar trend
between the two genotypes (Fig 2G). These data suggest that, dif-
ferently from wt, null neurons did not integrate into an increasingly
cohesive network, indicative of a defect in neuronal maturation.
Noticeably, the parameters describing network activity in our model
were lower in magnitude compared to primary neurons, as expected
given the different level of maturity displayed by the two in vitro
models (Chiacchiaretta et al, 2017).
After measuring spontaneous activity, we studied the evoked
response upon exposure to 100 µM of the voltage-activated K+ chan-
nels blocker 4-aminopiridine (4AP) at DIV22 (Fig 2H–K). Although
the fold increase in WMFR was comparable between the two geno-
types (2.93  0.3 in wt and 3.6  0.8 ko samples; Student’s t-test;
Fig 2J), when considering the absolute WMFR values, the response
was twofold higher in wt samples compared to null samples
(2.99 Hz  0.4 in wt and 1.52 Hz  0.5 ko samples; *P < 0.05;
Student’s t-test; Fig 2K). These results demonstrate that networks
established from Mecp2 null differentiated NPCs are less active
compared to wt, in line with previous data (Kron et al, 2012;
Bedogni et al, 2016; Katz et al, 2016; Sceniak et al, 2016).
We next analyzed the growth of dendritic branches. The
dendritic complexity analyzed in wt and Mecp2 null neurons
increased through time in both genotypes (Fig 2L). However, start-
ing from DIV14, null neurons exhibited a poorer dendritic growth
compared to wt, as we detected a significant reduction of both
number of intersections and total dendritic length (**P < 0.01,
*P < 0.05; two-way ANOVA followed by Bonferroni post hoc test;
Fig 2M and N), while maximal dendritic length appeared reduced at
earlier time points (**P < 0.01, *P < 0.05; two-way ANOVA
followed by Bonferroni post hoc test; Fig 2O). Similarly, the percent-
age of polarized null neurons (see Materials and Methods for defi-
nition) resulted significantly diminished from DIV18 (73.8%  3.2
and 55.8%  2.7 in wt and null neurons, respectively; *P < 0.05;
two-way ANOVA followed by Bonferroni post hoc test; Fig 2P).
Eventually, and in line with previous findings (Wang et al, 2013;
Bittolo et al, 2016; Sampathkumar et al, 2016), NPC-derived null
neurons at DIV14 showed a reduction in soma size (85.8 µm2  1.8
and 61.7 µm2  0.9 in wt and null neurons, respectively;
***P < 0.001, Student’s t-test; Fig 2Q).
Overall, these functional and morphological data confirm that our
model reproduces many of the typical maturation defects generated
in vivo and in vitro by the absence of Mecp2 (Baj et al, 2014; Rietveld
et al, 2015; Bedogni et al, 2016; Sampathkumar et al, 2016).
The enhancement of glutamatergic transmission within an
early time window produces rescue effects that persist at later
time points
Our hypothesis is that reduced activity-dependent signaling in Mecp2
null neurons contributes to their defective transcription and morpho-
logical immaturity, which further reinforce a defective response to
stimuli. We thus studied whether a pharmacological enhancement of
neuronal excitability could rescue the observed maturation defects.
With this aim, maturing neurons were treated with Ampakine
CX546, a positive modulator of glutamatergic transmission. CX546
binds the glutamate-activated AMPA receptor on the subunits GRIA1
and GRIA2 reducing desensitization and slowing channel closure
(Nagarajan et al, 2001; Lynch & Gall, 2006). Initially, we measured
the levels of Gria2 at different developmental stages to verify
whether both wt and null cultures had comparable potential to
respond to the drug. We found that wt and Mecp2 null neurons
expressed similar amounts of the AMPA subunit at DIV3 and 7,
while at DIV14 null neurons showed a significantly reduced expres-
sion compared to wt (0.60  0.03 in wt and 0.46  0.03 in null
samples; **P < 0.01, two-way ANOVA followed by Bonferroni post
hoc test; Fig EV3B). Moreover, we investigated the involvement of
the AMPA receptor in mediating Ampakine effects by acutely expos-
ing cells to CX546 alone or simultaneously with the AMPA receptor
antagonist NBQX. As expected, NBQX inhibited the drug effects on
Akt phosphorylation (*P < 0.05; one-way ANOVA followed by
Tukey’s post hoc test; Fig EV3A). Based on published data, we then
tested longer exposure of two different doses of CX546 (10 and
20 µM; Schitine et al, 2012). Daily addition of 10 µM CX546 from
DIV7 to DIV10 did not produce toxic effects, while chronic exposure
to 20 µM (from DIV1 to DIV10) resulted in only 50% cell survival
(Fig EV3C). We thus designed a protocol in which 20 µM CX546 was
added every day to the cultures for 4 days and then washed out. To
assess whether different time windows of CX546 exposure could
produce different rescue effects, CX546 was added either from DIV3
to DIV6 or from DIV7 to DIV10 (Fig 3A) followed by washout.
Samples were then collected for morphological and transcriptional
assessments at DIV14. As shown in Fig 3B and C, CX546 treatments
produced a significant amelioration of several morphological param-
eters in null neurons, including dendritic length, number of neurite
intersections, and soma size. Notably, the effects were slightly
stronger when the drug was early administered (**P < 0.01,
*P < 0.05; one-way ANOVA followed by Tukey’s post hoc test); no
trophic effect was observed in wt samples (Appendix Fig S1A–D). To
confirm the contribution of reduced activity to the typical immaturity
displayed by Mecp2 null neurons, we also tested the effects of the
addition of 4 mM KCl on neuronal morphology. In line with our
previous results, we found that a chronic exposure of differentiating
neuronal cultures to KCl rescued the dendritic complexity of Mecp2
null neurons (***P < 0.001, **P < 0.01, *P < 0.05; one-way ANOVA
followed by Tukey’s post hoc test; Fig EV4A–D). Importantly, such
treatment resulted more effective when applied early during
neuronal maturation compared to a late treatment (from DIV0 to
DIV7 followed by washout or from DIV7 to DIV14, respectively;
***P < 0.001, **P < 0.01, *P < 0.05; two-way ANOVA followed by
Bonferroni post hoc test; Fig EV4E–G). Next, we assessed transcrip-
tion on RNA samples prepared from wt controls and null neurons
treated with either Ampakine or vehicle and collected at DIV14
(Fig 3D–H). Initially, as for Fig EV2A and B, we used PCA to qualita-
tively address whether CX546 reduced the transcriptional distance of
null from wt samples. To this purpose, we analyzed only those tran-
scripts that resulted unaffected by batch effects (43 genes;
Appendix Fig S2). As depicted in panel E, when the analysis was
performed after early CX546 exposure (DIV3-DIV6), the transcrip-
tional distance from wt and null treated samples appeared reduced
compared to basal condition (Fig 3D). In line with this, a detailed
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Figure 3. Early exposure to CX546 rescues selected morphological and transcriptional defects of null neurons.
A Schematic representation of the CX546 treatment. The drug was added to the cell medium from DIV3 to DIV6 (early) and from DIV7 to DIV10 (late); a complete
washout of the medium was performed at the end of each treatment (DIV7 and DIV11, respectively).
B, C Five morphological parameters were measured in untreated and treated null neurons at DIV14. One-way ANOVA indicated a significant treatment effect for the
maximal dendritic length (F = 6.306; P = 0.0039), total dendritic length (F = 4.880; P = 0.0126), number of intersections (F = 10.70; P = 0.0003), and soma area
(F = 7.721; P = 0.0015). Tukey’s multiple comparison test was used to assess differences between null neurons and early and late treated neurons. *P-value < 0.05;
**P-value < 0.01; ***P-value < 0.001. The variation of each of the selected parameters is summarized in the radar plot (C). Sample size (panels B, C): n ≥ 18 wells
for ctrl group and n ≥ 10 wells for the treatment groups deriving from three independent preparations; for each well, we measured at least 15 cells. Each point is
representative of a single well. Values are represented as mean  SEM.
D–H The three PCA analyses are based on the 43 genes selected in Appendix Fig S2 and highlight the transcriptional differences between wt (in blue), ko (in red), and ko
CX546 treated (light and dark green for early and late treatment, respectively) samples. Bar graphs represent the expression values (mean  SEM) of 27 genes,
selected for their down-regulation in null samples at DIV14 (P-value < 0.07; see Appendix Fig S2), after CX546 administration in the two different time windows
(early in G and late in H). One-way ANOVA followed by Dunnett’s multiple comparison test was used to compare the expression of each gene between Mecp2 null
early- and late-treated samples and their corresponding untreated controls (set to 1, red dotted line). *P-value < 0.05; **P-value < 0.01, ***P-value < 0.001,
****P-value < 0.0001. Sample size: n ≥ 8 wells deriving from two independent preparations. Each point is representative of a single well.
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representation of the 27 transcripts selected for their down-regula-
tion between wt and null samples (Appendix Fig S2), showed that 14
of them were increased to levels that were significantly higher
compared to untreated null samples (**P < 0.01, *P < 0.05; one-way
ANOVA followed by Dunnett’s post hoc test; red dotted line in
Fig 3G). Importantly, CX546 appeared more effective when added
from DIV3 to DIV6 compared to DIV7-DIV10, as shown by PCA anal-
yses in Fig 3E and F. Accordingly, among the selected 27 genes only
2 were significantly increased (***P < 0.001, *P < 0.05; one-way
ANOVA followed by Dunnett’s post hoc test; Fig 3H). To be noticed,
these treatments produced limited or no significant transcriptional
change on wt neurons (Appendix Fig S1E and F).
We next tested the effectiveness of CX546 on primary neuronal
cultures produced from null and wt E15 embryonic cortices, a model
that has been thoroughly used to highlight functional defects driven
by the lack of Mecp2. In line with our previous observations (Bedogni
et al, 2016), primary neurons responsiveness to extracellular stimuli
was impaired by the lack of Mecp2, as indicated by the analysis of
intracellular Ca2+ transients induced by 100 µM NMDA (Fig 4A–C).
The two bell-shaped curves representing the distribution of the
responses of DIV14 wt (in blue) and null samples (in red) in fact did
not overlap, as the null curve shifted toward smaller responses.
However, after early exposure to CX546, the null curve overlapped
with that of wt (Fig 4B), therefore suggesting that the early treatment
rescued the reduced responsiveness to NMDA. On the contrary, the
late treatment with CX546 produced no rescue (Fig 4C), reinforcing
the higher effectiveness of the early treatment (***P < 0.001,
*P < 0.05; two-way ANOVA followed by Bonferroni post hoc test).
Next, we focused on the excitatory-to-inhibitory developmental
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intracellular level of chloride, which progressively diminishes
throughout neuronal development, enabling the transition of GABA
responses from excitatory to inhibitory (Ben-Ari, 2002; Ben-Ari
et al, 2007). The molecular mechanisms driving these events are
affected by the lack of Mecp2, resulting in a higher intracellular
chloride level in mature null neurons (Tang et al, 2016). In line with
these findings, the intracellular chloride, imaged at single-cell reso-
lution with MQAE dye (Corradini et al, 2018), was higher in null
neurons compared to control at each time point we analyzed (the
MQAE signal is inversely proportional to the chloride content;
#P < 0.05, **P < 0.01; two-way ANOVA followed by Bonferroni post
hoc test; Fig 4D and E). Once again, the early exposure of null
neurons to CX546 restored an intracellular chloride level compara-
ble to wt neurons (Fig 4F), while no effect was observed in the late
time window of treatment (***P < 0.001; one-way ANOVA followed
by Tukey’s post hoc test; Fig 4G).
Eventually, we focused on transcription, testing also in primary
neurons the ability of CX546 to positively modulate the expression
of genes that are typically downregulated in the absence of Mecp2
(Fig 4I). To confirm that CX546 affected transcription through the
positive modulation of activity, we included in the analyses samples
simultaneously treated with CX546 and the L-type Calcium channels
blocker Nifedipine. As expected, the early treatment with CX546
induced the expression of several genes (Gabbr1, Gap43, Grin1,
Kcc2, and Tuj1) that are otherwise downregulated in null neurons
(Fig 4H and I). On the contrary, much of these transcriptional
effects were not observed in the presence of Nifedipine, thus con-
firming both the involvement of voltage-gated L-type calcium chan-
nels in the mechanism of CX546 action and the ability of increased
neuronal activity to ameliorate selected Mecp2-dependent transcrip-
tional deficiencies. Importantly, CX546 drove a reduction in the
expression of Rest, a transcriptional repressor that is generally
upregulated in Mecp2 null samples and cooperates with Mecp2 in
the regulation of Kcc2 expression (Abuhatzira et al, 2007; Tang et al,
2016; ***P < 0.001, **P < 0.01, *P < 0.05, #P < 0.05; one-way
ANOVA followed by Tukey’s post hoc test). In line with this, we
found that CX546, but not CX546 + Nifedipine, increased the ratio
of the expression levels of Kcc2 and Nkcc1 (1.8  0.18 in CX546-
treated samples and 1.1  0.11 in CX546 + Nif-treated samples;
**P < 0.01 one-way ANOVA followed by Tukey’s post hoc test;
panel J). These transcriptional effects fit well with our functional
data and suggest a faster rate of maturation of GABA signaling.
Early treatment with Ampakine ameliorates behavioral deficits
of Mecp2 null mice
Prompted by the rescue effects driven by the early in vitro exposure
to CX546, we assessed its effectiveness in vivo. To this aim, we used
the CD1 Mecp2tm1.1Bird RTT mouse model focusing on hemizygous
ko males (Cobolli Gigli et al, 2016). Although RTT mainly affects
females, explorative studies are generally performed on mutant
male mice that present more robust and consistent phenotypes.
Mecp2 null and wt mice were daily injected subcutaneously with
either CX546 (40 mg/kg) or vehicle from P3 to P9 and the validity of
the treatment was evaluated starting from P30 testing multiple read-
outs (Fig 5A). As expected, the lifespan of CD1 ko mice treated with
vehicle was markedly reduced compared to the wt group, showing
50% of survival animals at P80 (Cobolli Gigli et al, 2016; Fig 5B).
However, when CX546 was injected in the selected early time
window, mice showed a significant extension of their lifespan, with
90% of animals being able to survive after P88, an age reached only
by a minority of the ko-untreated progeny. Indeed, the average
survival of CX546-treated ko animals was P110 (Fig 5B). This effect
on lifespan was accompanied by a significant improvement of the
◀ Figure 4. Mecp2 null neuronal network responsiveness is rescued by early treatment with CX546.
A Representative images of DIV14 wt and Mecp2 null primary cortical neurons loaded with Fluo-4 before and after NMDA 100 µM exposure. High fluorescent signals
correspond to high calcium levels. Dotted circles are representative of the Region Of Interest (ROI) used during the analysis. Scale bars: 20 µm.
B, C The graphs represent the binned distribution of the magnitude of NMDA-induced calcium transients in wt (in blue), Mecp2 null (in red), and treated Mecp2 null
(light and dark green for early and late treatment, respectively). The distribution of responses on X-axis are expressed as percentage compared to wt (100%), values
on Y-axis refer to percentage of cells over total (100%). Two-way ANOVA followed by Bonferroni post hoc multiple comparison test was used to compare calcium
responses between wt, Mecp2 null and Mecp2 null early (B) and late treated (C) neurons. *P-value < 0.05 ***P-value < 0.005. Red *: comparison between wt and
ko; green *: comparison between wt and treated ko. Inserts b’ and c’ represent the protocols of CX546 exposure; dotted lines indicate the washout of the drug.
Values are represented as mean  SEM. Sample size: n = 11 and 10 animals for wt and Mecp2 null control groups (for a total of 710 and 670 cells measured,
respectively) and n = 4 and 6 animals for early and late CX546-treated groups (for a total of 270 and 360 cells measured, respectively).
D Representative images of DIV6 and DIV14 wt and Mecp2 null primary cortical neurons loaded with MQAE dye. High levels of fluorescence correspond to low level of
intracellular chloride. Dotted circles are representative of the Region Of Interest (ROI) used during the analysis. Scale bars: 20 µm.
E Line graphs represent intracellular chloride concentration at different consecutive time points in wt and Mecp2 null neurons. Two-way ANOVA indicated a
significant effect for both time (F(2, 1541) = 840.9 and P < 0.0001) and genotype (F(1, 1541) = 155.7 and P < 0.0001). Bonferroni post hoc test revealed a
statistically significant reduction of Mecp2 null MQAE intensity at all the analyzed time points. **P-value < 0.01; #P < 0.0001. Values of MQAE intensity are
represented as mean  SEM. Sample size: n ≥ 200 cells from three different embryos per genotype.
F, G Violin plots represent the average values of MQAE intensity for early (F) or late (G) treated null neurons and their relative controls. One-way ANOVA followed by
Tukey’s multiple comparison test was used to compare null control neurons and null-treated neurons to wt neurons. ***P < 0.001; ****P < 0.0001. The central line
of the violin plot is the median while the two dotted lines represent the upper and lower quartiles. Sample size: n ≥ 300 cells from five different embryos per
genotype.
H Schematic representation of CX546 and Nifedipine administration; dotted line indicates drug wash out.
I, J In I, one-way ANOVA was used to compare the expression of 9 neuronal genes between Mecp2 null primary neurons (set to 100), null neurons treated with CX546
from DIV1 to DIV4 and null neurons treated with CX546 and Nifedipine from DIV1 to DIV4. * refers to differences between Mecp2 null untreated neurons and
Mecp2 null neurons treated with CX546 (*P-value < 0.05; **P-value < 0.01; ***P-value < 0.001); # refers to differences between Mecp2 null neurons treated with
CX546 and null neurons treated with both CX546 and Nifedipine (#P-value < 0.05; ##P-value < 0.01). Panel J shows the ratio between the expression level of Kcc2
and Nkcc1 (expressed as 2-Δct). Box plot shows the median (central band), the lower and upper quartiles (boxes), and the max and min values (whiskers) from at
least 3 wells obtained from four different embryos. One-way ANOVA was used to compare the effects of the different treatments on null neurons compared to the
untreated ones. **P-value < 0.01. Sample size: n ≥ 3 wells from four different embryos.
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overall health of KO-treated mice. First, the thoroughly described
reduction in body weight of Mecp2 null mice was markedly recov-
ered after the treatment with CX546 at all the analyzed time points
(****P < 0.001, **P < 0.01, *P < 0.05; two-way ANOVA followed
by Bonferroni post hoc test; Fig 5C). By means of the scoring system
typically used to assess the worsening of the health conditions of
null mice (Guy et al, 2001), we noticed a marked difference in the
severity between untreated and treated ko animals during the overt
phase of the pathology (Fig 5D). At P70, in fact, while 56% of
untreated ko mice exhibited a severe RTT score (>6), only 27% of
CX546-treated mice felt in this highly symptomatic range. Such dif-
ference was even more evident at P80, when we detected that all
the untreated ko mice felt in the highest severity score, as opposed
to only 40% of the CX546-treated mice. Among the phenotypes
observed during the scoring assessment, hind limb clasping, one of
the classical parameters used to assess neurological defects in RTT
animal models, was ameliorated after CX546 treatment (Fig 5E).
Next, we assessed the effectiveness of the treatment in ameliorating
defects typically displayed by RTT mouse models in locomotor
activity, coordination, and spatial memory. The CX546 treatment
significantly ameliorated the performances of P45 mice on the accel-
erating rotarod test, as shown by the assessment of learning ability
(through three successive trials; Fig 5F) and motor coordination
(last trial; **P < 0.01, *P < 0.05; two-way ANOVA followed by
Bonferroni post hoc test; Fig 5G). At the same age, we tested the
animals in the Novel Object Recognition test (NOR) proving that the
early exposure to Ampakine improved the ability of ko animals to
discriminate between two different objects (**P < 0.01, *P < 0.05;
two-way ANOVA followed by Bonferroni post hoc test; Fig 5H and
Appendix Fig S3). Notably, CX546 treatment did not affect both
physical and behavioral performance of wt-treated animals
(Appendix Fig S3).
Interestingly, and in good accordance with Ampakine effects
(Lauterborn et al, 2003; Lynch & Gall, 2006), the amelioration of
A
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Figure 5. Early treatment with Ampakine ameliorates behavioral deficits of Mecp2 null mice.
A Schematic representation of the in vivo CX546 administration protocol.
B Kaplan Mayer test shows an improved lifespan of Mecp2 null CX546-treated animals compared to Mecp2 null control animals. Sample size: wt = 11, ko = 16, ko
treated with CX546 = 11. Gehan–Breslow–Wilcoxon test was used to compare the two groups. **P-value < 0.01.
C The body weight of mice was assessed at four different time points (P30, P50, P70, and P90). Two-way ANOVA indicated a significant effect for both time (F(1, 813,
47, 13) = 421.1 and P < 0.0001) and treatment (F(2, 33 = 7.540 and P < 0.0001). Tukey’s multiple comparison test was used to compare within each time point the
effect of the CX546 treatment on Mecp2 null mice. **P-value < 0.01; ****P-value < 0.0001. Values are represented as average  SEM. Sample size: n = 10 wt and
n = 27 ko (16 treated with vehicle and 11 treated with CX546). Each dot represents a single animal.
D, E Severity scores were calculated at different time points (P55, P70, P80 in D). The score for hind limbs clasping was assessed twice a week starting from P30 (E).
Sample size for D and E: n = 10 wt treated with vehicle and n = 20 ko (9 treated with vehicle and 11 treated with CX546). Data are represented as mean  SEM.
F, G Line graph (F) shows mice motor learning assessed on the accelerating rotarod during three consecutive trials. Two-way ANOVA indicated a significant effect of
time (F(2, 21) = 5.490 and P = 0.0121) and genotype (F(2, 33) = 16.33 and P < 0.0001). Bonferroni multiple comparison test highlighted a significant increase in the
latency to fall between trial 1 and trial 3 only for null mice treated with CX546. *P-value < 0.05; **P-value < 0.01. The scatter plot (G) shows latency to fall (in
seconds) on the accelerating rotarod in the last trial. One-way ANOVA was used to compare ko mice and ko-treated mice to the wt group. The Tukey’s multiple
comparison test highlighted a significant reduction in the latency to fall between wt and ko but not between wt and ko treated with Ampakine; **P-value < 0.01.
Values are represented as average  SEM. Sample size: n = 6 wt treated with vehicle and n = 14 ko (6 treated with vehicle and 8 treated with CX546). Each dot
represents a single animal.
H The graph shows the assessment of the discrimination index (DI) between two different objects for each mouse during the last trial of a Novel Object Recognition
test. One-way ANOVA was used to compare ko mice and ko-treated mice to the wt group. Tukey’s multiple comparison test highlighted a P-value of 0.07 between
wt and ko treated with vehicle but not between wt and ko treated with CX546. Data are represented as mean  SEM. Sample size: n = 8 wt treated with vehicle
n = 12 ko (6 treated with vehicle and 6 treated with CX546). Each dot represents a single animal.
I, J The graphs show the expression level of Bdnf (I) and Kcc2 (J) in cortical samples obtained from P45 animals. One-way ANOVA was used to assess difference in the
expression of the two selected genes between wt, ko e CX546-treated ko animals. For Bdnf expression (I), Tukey’s multiple comparison test highlighted significant
differences between both wt and ko and ko and ko treated with CX546 but no difference between wt and ko treated with CX546 (*P-value < 0.05; **P-
value < 0.01). For Kcc2 expression (J), Tukey’s multiple comparison test highlighted significant differences between wt and ko but no difference between wt and ko
treated (*P-value < 0.05). Data are represented as values  SEM. Sample size for I: n = 10 wt, n = 9 ko, and n = 6 ko treated with CX546. Sample size for J: n = 11
wt, n = 12 ko, and n = 7 ko treated with CX546. Each dot represents a single animal.
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Mecp2 null animal conditions was accompanied by rescued tran-
scriptional levels of Bdnf in P45 null cortices (P < 0.01, *P < 0.05;
one-way ANOVA followed by Tukey’s post hoc test; Fig 5, panel I).
Further, and in line with our in vitro results, CX546 treatment
rescued the Kcc2 transcriptional defect (Fig 5, panel J). To be
noticed, CX546 did not affect Bdnf and Kcc2 transcription in wt-
treated cortices (Appendix Fig S3).
Discussion
Recent preclinical and clinical studies demonstrate that besides the
importance of Mecp2 in maintaining neuronal structures (Guy et al,
2007; McGraw et al, 2011; Cheval et al, 2012; Nguyen et al, 2012),
its deficiency strongly affects embryonic and early postnatal devel-
opment (Ip et al, 2018), thus long before the full outbreak of symp-
toms (Cosentino et al, 2019; Zhang et al, 2019). We contributed to
this novel perspective by demonstrating that Mecp2 null neurons
display aberrant transcriptional profiles, reduced responsiveness to
stimuli and poor morphology already during early corticogenesis
(Bedogni et al, 2016; Cobolli Gigli et al, 2018). Based on the hypoth-
esis of a crucial role played by neuronal activity in the establishment
of mature neuronal networks (Spitzer, 2006), we investigated
whether the reduced responsiveness of Mecp2 null neurons partici-
pates to their poor transcriptional and morphological features that
would further contribute to the overall immaturity of the networks.
We thus tested the rescue potential of an early enhancement of
activity in in vitro and in vivo Mecp2 null models.
To enhance activity, we used the Ampakine CX546, a positive
modulator of AMPA glutamatergic receptors that upon glutamate
binding delays deactivation and desensitization (Lynch & Gall,
2006). The choice of CX546 was based on its ability to stimulate
dendritic outgrowth and maturation of in vitro differentiating
neurons (Schitine et al, 2012) and was further supported by the fact
that CX546 was already successfully used in preclinical studies on
RTT, although in later time windows compared to this study (Ogier
et al, 2007) and focusing on a different pathological mechanism
(Degano et al, 2014). Our data demonstrate that the maturation of
Mecp2 null neurons is sensitive to depolarization. In fact, by expos-
ing Mecp2 null neurons to KCl we rescued morphological parame-
ters, which was in line with the beneficial effects driven by CX546
on morphology, transcriptional levels, and network functions. By
enhancing activity, we thus restored each component of the already
described feed-forward cycle that ensures neuronal maturation
(Spitzer, 2006). In good accordance with our hypothesis, the early
treatment resulted more effective compared to the late one possibly
because during early time windows neuronal networks are more
plastic compared to later stages, when changes are restrained by
advanced differentiation. In fact, CX546 treatment increased the
levels of expression of Gap43 and Tuj1, two structural proteins that
are involved in synaptic plasticity and growth cones stability
(Benowitz & Routtenberg, 1997; Korshunova & Mosevitsky, 2010;
Tischfield & Engle, 2010). On the same line, CX546 exposure
increased transcription of the neurotrophin Bdnf, a master regulator
of plasticity (Lauterborn et al, 2003; Simmons et al, 2009) thor-
oughly associated with MeCP2 deficiency (Li et al, 2017; Renthal
et al, 2018). From a functional perspective, CX546 rescued the
responsiveness of null neuronal networks to stimuli, while
decreasing their intracellular Cl levels, which suggests a restored
responsiveness to GABA. This result fits with the recovered tran-
scriptional levels of Kcc2, the neuron-specific K+-Cl co-transporter
(KCC2) that is crucial for GABA signaling maturation (Ben-Ari,
2002; Ben-Ari et al, 2007) and its normalization in Rett syndrome
currently represents a promising therapeutic approach (Tang et al,
2016; Hinz et al, 2019; Tang et al, 2019; Lozovaya et al, 2019).
Importantly, Nifedipine, a voltage-gated calcium channels blocker,
restricted the observed transcriptional rescues, therefore proving the
importance of calcium signaling in controlling many transcriptional
programs involved in neuronal development (Rosenberg & Spitzer,
2011). Our data thus support the concept of a deficit of calcium-
dependent maturation mechanisms in neurons lacking Mecp2
(Bedogni et al, 2016).
A further validation to our hypothesis derived from the benefits
we detected in Mecp2 null animals treated from P3 to P9 with
CX546. Indeed, we demonstrated that such a short and early treat-
ment delays the progression of the disorder. In fact, ko-treated mice
manifested a significantly prolonged life span, an amelioration of
motor and cognitive functions (evaluated 30 days after the treat-
ment) and a delayed progression of typical phenotypes that were
still evident 70 days after the last administration with CX546.
The benefits produced by early CX546 treatment were further
confirmed by the rescued transcriptional levels of Bdnf and Kcc2
observed in the cortex of P45 null animals, which reinforces our
in vitro results and further suggests the role of GABA signaling in
mediating ampakine-positive effect. Overall our in vivo results
suggest a remarkably long-lasting effect of the treatment, thus rein-
forcing the role of early changes in plasticity on the functions of
Mecp2 null neuronal networks. While the alteration of the already
described feed-forward cycle during early development does not
produce overt symptoms, such alterations likely concur to the estab-
lishment of an improper program of gene expression that takes part
to the outbreak of overt symptoms and the typical Mecp2 null
network dysfunctions later in life (Dani et al, 2005; Durand et al,
2012; Nelson & Valakh, 2015; Sceniak et al, 2016). We thus propose
the existence of an early molecular phase of Rett syndrome during
which the initial developmental trajectory undertaken by maturing
null networks deranges from physiology. We believe that a thor-
ough comprehension of the mechanisms playing a pathogenic role
during this phase will likely reveal novel therapeutic strategies.
The importance of targeting early neuronal maturation has
already been implied by previous preclinical and clinical studies
(Marın, 2016). Indeed, the injection of a truncated form of IGF1 in
pre-symptomatic (P15) Mecp2 null and heterozygous mice rescued
neuronal morphology, synaptic density, and network plasticity (Tro-
pea et al, 2009). Further, in clinical trials, IGF1 (Trofinetide)
revealed more effective when administered at pediatric ages
compared to adolescence/adult (Banerjee et al, 2019). Similarly, the
efficacy of the GABAB receptor agonist Arbaclofen in the cure of
Fragile-X syndrome symptoms resulted strictly dependent to the
timing of treatment (Berry-Kravis et al, 2018). Accordingly, in a
mouse model of epileptic encephalopathy, GABAergic tone modula-
tors ensured phenotypic rescue only when administered within the
first 2 weeks of life (Marguet et al, 2015).
RTT is generally considered a reversible condition and the ability
of CX546 to recover Bdnf expression and LTP in the adult Mecp2
null brain has already been suggested (Ogier et al, 2007). However,
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these studies did not assess the persistence of the effects and the
behavioral domains that benefitted from the treatment. Although we
suggest that an early enhancement of activity might have a higher
positive effect than later ones, such paradigm of CX546 administra-
tion may be impractical for translational approaches. Thus, in the
future we will apply longitudinal studies and test different time
windows of treatment to gain preclinical insights. Further, we will
assess whether the in vivo timing of CX546 exposure should be
enlarged to ensure wider and possibly stronger rescue effects. Even-
tually, we will test the benefits of repeating the treatment in order to
ensure the preservation, rather than the establishment alone, of
functional neuronal networks; promising data will be confirmed in
Mecp2 heterozygous females, as requested for any study testing a
novel therapeutic approach for RTT (Katz et al, 2016).
All in all, our study suggests that overt symptoms are the final
outcome of a pathogenic process that likely starts very early during
development, implying the importance of re-evaluating the defi-
nition of the “pre-symptomatic” phase of Rett syndrome (Bedogni
et al, 2016; Cosentino et al, 2019; Zhang et al, 2019).
Materials and Methods
Animals and tissues
The Mecp2 mouse strain was originally purchased from Jackson
Laboratories (B6.129P2(C)-Mecp2tm1.1Bird/J) and transferred on a
CD1 genetic background. The phenotypes affecting these animals
have been previously described (Guy et al, 2001; Cobolli Gigli et al,
2016). Mouse genotypes were determined through PCR on genomic
DNA purified from tail biopsy obtained within the second and the
third week of life (Cobolli Gigli et al, 2016). Time pregnant females
were generated by crossing overnight wt CD1 males with Mecp2/+
heterozygous females; the day of vaginal plug was considered E0.5.
For RNA processing, brains were collected from anesthetized mice
(Avertin, Sigma-Aldrich), dissected cortices were then rapidly frozen
on dry ice and stored at 80°C. All procedures were performed in
accordance with the European Community Council Directive 86/
609/EEC for care and use of experimental animals; all the protocols
were approved by the Italian Ministry for Scientific Research and by
the local Animal Care Committee.
Neuroprecursors and neurons cultures
Cerebral cortices were dissected from E15.5 mouse embryos and
pulled after genotyping. Generation and maintenance of neuro-
sphere cultures were performed as already described (Cobolli Gigli
et al, 2018; Fig 1A). To induce differentiation, neurospheres were
dissociated in single-cell suspensions and plated on Matrigel-coated
surfaces. Until adhesion, cells were grown in complete medium
(DMEM/F12, 0.6% glucose, 1% L-glutamine, 1% Pen/Strep, 4 µg/
ml heparin, 1× hormone mix, 20 ng/ml epidermal growth factor
(EGF), 10 ng/ml basic fibroblast growth factor (bFGF)). EGF and
bFGF were withdrawn, respectively, 2 and 3 days after plating
before the addition of fetal bovine serum (FBS 2%). This last
passage was considered DIV0. Generally, cells were plated at a
density of 26,000 cells/cm2. To enhance activity, CX546 (Tocris
Bioscience) was dissolved in DMSO and diluted 1:10 in water to
obtain the working solution. The drug was added daily for 4 days
directly to the medium from either DIV3 or DIV7 reaching a final
concentration of 20 µM. An equal volume of 10% DMSO in water
was added to controls. CX546 was washed out following the last
administration by replacing the cell medium.
Primary neuronal cultures were prepared from E14.5 mouse cere-
bral cortices (Gandaglia et al, 2018). 15,000 neurons/well were
plated on poly-L-lysine (0,1 mg/ml; Sigma-Aldrich) coated 96 multi-
wells (Greiner) and cultured in Neurobasal medium supplemented
with B27, L-Glutamine, and Pen-Strep. CX546 (10 µM) or corre-
sponding volumes of DMSO were directly added to the medium at
DIV1 and DIV3 for the early treatment and at DIV7 and DIV9 for the
late treatment. Nifedipine (10 µM; Tocris Bioscience) was added at
the same time of CX546 only within the early time window at DIV1
and DIV3. Drugs were then washed out by changing the medium at
DIV5 or DIV11.
Cell immunofluorescence
Cells were fixed with 4% PFA for 20 min, rinsed with PBS, and
incubated for 1 h in blocking solution (10% horse serum, 0.1%
Triton X-100). Cells were then incubated overnight at 4°C with
primary antibodies diluted in blocking solution at the concentrations
reported in Appendix Table S2. After PBS washing, cells were incu-
bated for 1 h at room temperature in secondary antibodies (1:500 in
blocking solution; Molecular Probes). Before mounting, cells were
rinsed with PBS and nuclei were counterstained with DAPI (Invitro-
gen). An upright Nikon microscope was used for acquisitions, while
ArrayScan XTI HCA reader (Thermo Fisher Scientific) was used for
all the high-throughput acquisitions. For the measurement of Neun
intensity, images were all acquired with the same setting and then
the signal was manually measured with ImageJ. Excel and Prism
were used to elaborate data.
RNA purification, cDNA synthesis, and quantitative PCR
NPC and primary neurons for qPCR Dynamic Array microfluidic
chip assays
Cells were rinsed once with PBS and lysed in PurezolTM (300 µl for
roughly 30,000 cells; Bio-Rad). RNA was isopropanol precipitated
and treated with DNAse I (Sigma-Aldrich), re-extracted with phenol-
chloroform and isopropanol precipitated over night at 20°C. RNA
pellets were dissolved in 10 µl of TE buffer. RNA concentration and
quality were checked using Bioanalyzer RNA 6000 Nano chips (Agi-
lent). 50 ng of total RNA was reverse-transcribed using Superscript
IV Reverse Transcriptase (Thermo Fisher). 1 ng of cDNA for each
sample was pre-amplified using a 0.2X pool of 74 primers (TaqMan;
Thermo Fisher; Appendix Table S1) for 18 cycles using PreAmp
Master Mix (Fluidigm) to enable multiplex sequence-specific ampli-
fication of targets. Pre-amplified cDNAs were then diluted and
assessed using a 96 × 96 qPCR Dynamic Array microfluidic chip
(Fluidigm) following the manufacturer’s instructions. Baseline
correction was set on Linear (Derivative) and Ct threshold method
was set on Auto (global). To normalize, for each sample a “pseudo-
gene” (D’haene et al, 2012) was obtained by averaging the Ct value
of each gene depicted in Appendix Table S1 except for Mecp2. Each
sample was then normalized against its “pseudogene.” Excel, Prism,
and R were used to elaborate data.
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DIV22 NPCs for quantitative RT–PCR
Cells were rinsed once with PBS and lysed in PurezolTM (300 µl for
roughly 30,000 cells; Bio-Rad). RNA was isopropanol precipitated
and treated with DNAse I (Sigma-Aldrich), re-extracted with phenol-
chloroform and isopropanol precipitated over night at 20°C. RNA
pellets were dissolved in 10 µl of TE buffer. RNA quantity was
checked using NanoDrop (Thermo Fisher Scientific). 100 ng of RNA
was then retro-transcribed using the RT2 First Strand kit (Qiagen).
qRT–PCR results depicted in the Fig EV2 were performed using
SYBR green (Life Technologies) as fluorescent dye. Primers used for
the analyses are reported in Appendix Table S1. Excel (Microsoft)
and Prism (GraphPad) were used to elaborate data.
Tissues for quantitative RT–PCR
Cortices were lysed in 500 µl of PurezolTM (Bio-Rad). RNA was
isopropanol precipitated and treated with DNAse I (Sigma-Aldrich),
re-extracted with phenol-chloroform and isopropanol precipitated
over night at 20°C. RNA pellets were dissolved in 20 µl of Nucle-
ase free water (Sigma-Aldrich). RNA quantity was measured using
NanoDrop. 1,000 ng of RNA was then retro-transcribed using the
RT2 First Strand kit (Qiagen). qRT–PCR results depicted in Fig 5 and
in the Appendix Fig S3 were performed using SYBR selected master
mix (Applied Biosystems) as fluorescent dye. Primers used for the
analyses are reported in Appendix Table S1. Excel (Microsoft) and
Prism (GraphPad) were used to elaborate data.
Western blots
Neurons from 6-multiwell plates were lysed in ice-cold lysis buffer
(50 mM Tris–HCl, pH 7.4, 150 mM NaCl, 5 mM EDTA, 1% NP-40,
1× complete EDTA-free protease inhibitor cocktail (Roche) and 1×
PhosSTOP (Roche)) for 30 min on ice and then centrifuged for
30 min at 10,000 g (4°C). Protein concentrations were measured by
the bicinchoninic acid (BCA) assay kit (Thermo Fisher Scientific).
Equal amounts of protein lysates were separated on TGX Stain-Free
gel (Criterion 12 wells 4–15%; Bio-Rad). Before transfer, a stain-free
gel image was acquired by ChemiDoc Touch Imaging System (Bio-
Rad) and used to quantify results. Proteins were blotted on a nitro-
cellulose membrane (Trans-blot Turbo Nitrocellulose Transfer
Packs; Bio-Rad) using the Trans-blot SD semidry apparatus (Bio-
Rad). Membranes were incubated 1 h in blocking solution (Tris-
buffered saline containing 5% nonfat milk and 0.1% Tween-20, pH
7.4) and then incubated overnight (4°C) with the primary antibody
diluted in blocking solution. The following primary antibodies were
used: anti-AKT (4685; Cell Signaling; 1:2,000) and anti-phospho-
AKT (Ser473) (4060; Cell Signaling; 1:2,000). After 3 washes in TBS-
T, blots were incubated with the appropriate HRP-conjugated
secondary antibody (Peroxidase-conjugated AffiniPure Goat anti-
rabbit IgG (H + L), Jackson ImmunoResearch) for 1h at room
temperature. Immunocomplexes were visualized using the ECL
substrates kit from Cyanagen and the Bio-Rad ChemiDocTM System.
Quantification of bands was performed using the Image Lab 5.2.1
Software (Bio-Rad).
MEA recordings
Neuroprogenitors were plated at a density of 85,000 cells/well onto
12-well planar MEA chips (Axion BioSystems, Atlanta, GA),
comprising 64 electrodes/well. Spontaneous extracellular activity
was recorded with Axion Biosystems software (Axion Integrated
Studio), by individually setting a voltage threshold for each channel
equal to seven times the standard deviation of the average root
mean square (RMS) noise level. Single extracellular APs were
detected by threshold crossing of 200 Hz high-pass filtered traces.
Spike detection was carried out using the Axion BioSystems soft-
ware Neural Metric Tool. Evoked extracellular activity was
measured after addition of 100 µM 4-AP directly to cell medium. An
electrode was defined active when it registered at least 2 spikes/
min. Weighted mean firing rate (WMFR) was expressed as mean
number of spikes per second calculated on the active channels of
the network. Bursts within single channels were identified by apply-
ing an interspike interval (ISI) threshold algorithm (Chiappalone
et al, 2005) by defining bursts as collections of a minimum number
of spikes (Nmin = 5) separated by a maximum interspike interval
(ISImax = 100 ms). Only wells showing at least three active elec-
trodes were included in the analysis.
Automated analysis of calcium transients
Primary cortical neurons were loaded with 2 µM Fluo-4 (Invitrogen)
in KRH (Krebs’–Ringer’s–HEPES containing (in mM): 125 NaCl; 5
KCl; 1.2 MgSO4; 1.2 KH2PO4; 25 HEPES; 6 glucose; 2 CaCl2; pH 7.4)
for 30 min at 37°C and then washed once with the same solution.
Stimulation was performed automatically by using the liquid hand-
ling system of the ArrayScan XTI HCA Reader (Thermo Fisher Scien-
tific). To stimulate, one dose of NMDA (100 µM at the rate of 50 µl/
s) was added while images were digitally acquired with a high-reso-
lution camera (Photometrics) through a 20× objective (Zeiss; Plan-
NEOFLUAR 0.4 NA). Hoechst fluorescence was imaged as well. 70
frames were acquired at 1 Hz with 40 ms exposure time for Fluo-4
and 25 ms exposure time for Hoechst. At least 8 baseline images
were acquired before stimulation. The analysis was done with HCS
Studio software using SpotDetector bioapplication (Thermo Fisher
Scientific). Hoechst-positive nuclei were identified and counted, and
the mean intensity of the Fluo-4 signal was measured in the cell
body area of each cell; background intensity was measured and
subtracted from the mean intensity. Only cells with neuronal
morphology were included in the analysis. Calcium responses were
measured as ΔF/F0.
Chloride imaging recordings
Intracellular chloride measurements were performed using the N-
(ethoxycarbonylmethyl)-6-methoxyquinolinium bromide (MQAE)
(Biotium) chloride sensor. Briefly, cortical neurons at 14 DIV from
wt and Mecp2 null embryos were loaded with 5 lM MQAE for
45 min at 37°C in culture medium. Coverslips were then rinsed with
external solution (Krebs’–Ringer’s–HEPES (KRH): 125 mM NaCl,
5 mM KCl, 1.2 mM MgSO4, 1.2 mM KH2PO4, 2 mM CaCl2, 6 mM
glucose, and 25 mM HEPES–NaOH), pH 7.4 and transferred to the
recording chamber for acquisitions.
Olympus IX81 inverted microscope, 20× dry objective (Olympus,
UPLFLN NA 0.5) provided with MT20 widefield source and control
system with excitation 340 nm and emission filter centered at
500 nm were used. EXcellence RT software (Olympus) was used to
set up experiments and samples’ recordings. For each sample, a
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minimum of eight fields of interest (mean of cells observed for field,
20) were chosen to perform live imaging recordings. Offline analy-
ses were then made after defining ROIs centered to cell bodies and
measuring mean MQAE intensity during the time recording
window.
Morphological analyses
Morphological analyses were performed on images acquired with a
Nikon fluorescence microscope using a 20× objective. A binary
mask was created for each Tuj1-positive cell using Adobe Photo-
shop by an observer blind to the genotype and the treatment. Sholl
analyses and soma size were performed using the dedicated plugin
of ImageJ. The smallest circle was positioned at 5 µm from the
soma, while the largest at 300 µm. The distance between each circle
was 10 µm. The total dendritic length (TDL) and maximal dendritic
length (MDL) were evaluated using NeuronJ, a plugin of ImageJ.
For each neuron, the length of each dendrite (Lm) was measured
and the sum of such values defined the total dendritic length (TDL).
The polarization value was calculated as the ratio between the
maximal dendritic length and the average dendritic length. A ratio
equal or above 2 defines a polarized neuron; a culture is defined
polarized when at least 60% of neurons within it are polarized (Hor-
ton et al, 2006).
Cell viability assays
Cell viability was assessed through MTT assay (3-(4,5-dimethylth-
iazol-2-yl)-2,5-diphenyltetrazolium bromide; Sigma-Aldrich). MTT
(4 mg/ml) was diluted 1:10 in DMEM-F12 and added to each
well after medium withdrawal; plates were then incubated at
37°C for 4 h. Next, the solution was replaced by 100 µl of
DMSO, and the colorimetric signal assessed with a spectropho-
tometer (570 nm).
In vivo drug administration
Ampakine CX546 40 mg/kg was administered daily via a subcuta-
neous injection for 7 days (starting from P3) at the same time. The
drug was solubilized in ethanol (100%) and diluted 1:100 in saline
to obtain the working concentration. For the vehicle treatment,
ethanol (100%) was diluted 1:100 in saline.
Neurobehavioral characterization, phenotypic scoring, and
molecular assessments
Weight and phenotypic scoring assessments were evaluated twice a
week starting from P30. Severity score, typically used in RTT pheno-
typic assessments (Guy et al, 2001; Cobolli Gigli et al, 2016), was
used to group animals into three severity classes: absence of pheno-
types (0–2; light gray), mild phenotypes (≥ 2 to < 6; medium gray),
and severe phenotypes (≥ 6 to ≤ 8; dark gray), as described in Patrizi
et al (2016). The percentage refers to the number of mice falling in
one of the three severity classes over the total number of animals
per group. A total of 25 wt and 25 ko mice were used for lifespan
and phenotypic scoring. To be noticed, mice that rapidly lost weight
were euthanized for ethical reasons. The day of the sacrifice was
considered as the endpoint of lifespan assessment.
For molecular assessments (qRT–PCR on cortical samples),
mice were sacrificed at P45; a total of 16 wt and 16 ko mice
were used for this experiment. To avoid any bias, an investigator
blind to the genotypes and treatments of tested animals
performed all the analyses.
Behavioral assessment
Animals were maintained on an inverted 12 h light/darkness cycle
at 22–24°C. A total of 18 wt animals and 14 ko animals were
involved in the behavioral assessment. To avoid any bias, an inves-
tigator blind to the genotypes and treatments of tested animals
performed all the analyses.
Rotarod
Mice were assessed on an accelerating rotarod (Ugo-Basile, Stoelting
Co.). The test was carried out in 3 days, 2 days of training and
1 day of test. Each session consisted of three trials and each trial
lasted 5 min. Revolutions per minute (rpm) were set at an initial
value of 4 with a progressive increase to a maximum of 40 rpm.
Each trial ended when the mouse fell down or after 5 min. Latency
to fall was measured by the rotarod timer. Data were plotted and
subjected to statistical analysis with GraphPad Prism.
Novel Object Recognition (NOR)
The test was performed in an open square arena of 50 × 50 cm and
consisted of three different sessions. On day 1, during the first
session, mice were allowed to habituate with the arena for 10 min.
On day 2, mice underwent the training phase (5 min) in which they
were allowed to explore two identical objects. Object investigation
was defined as time spent sniffing the object when the nose was
oriented toward the object and the nose-object distance was 2 cm or
less. Time spent sniffing two identical objects during the familiariza-
tion phase confirmed the lack of an innate side bias. The total time
spent by the mice to explore the two objects in the cage was also
measured; if this was < 30 s (10% of the total time), the mouse was
not included into the final test (Appendix Fig S5). Finally, on day 3,
mice were tested (5 min) using two different objects. Recognition
memory, defined as spending significantly more time sniffing the
novel object than the familiar object, was calculated as Discrimina-
tion Index (DI): difference between the exploration time for the
novel object and the familiar object, divided by total exploration
time. The sessions were recorded with the video tracking software
EthoVision XT (Noldus).
Statistical analysis
Statistical analysis and plotting of data were performed with
GraphPad Prism. Student’s t-test was used for the statistical analysis
when wt were compared to Mecp2 null mutant samples. One-way
ANOVA was used to statistically compare the effects of early and
late addition of CX546, the effect of CX546 or CX546 plus Nifedipine
on Mecp2 null neurons and the effects of ampakine treatment on
mice. Data from the experiments on wt and null NPCs or neuronal
cultures at different DIVs, from the assessment of mice weight and
from the assessment of the exploration rate were analyzed by two-
way ANOVA. When there was a significant effect of treatment or
genotype, or a significant interaction between the variables (one-
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way or two-way ANOVA), appropriate post hoc test was applied. A
P-value of 0.05 was considered significant. A list of exact P-values is
provided as Appendix Table S3. Possible outliers within an experi-
mental group were identified with Grubb’s test and discarded from
the final analysis.
Each culture wells from in vitro analysis and mice from in vivo
experiments were randomly assigned to treatments, and for all the
experiments reported in the manuscript, the investigators were
blinded to the treatments and genotypes during data acquisition and
analyses.
Data availability
This study includes no data deposited in external repositories.
Expanded View for this article is available online.
Acknowledgements
We are grateful to ProRett Research, an Italian association that daily provides
us with both strive and funding to carry on our study on Mecp2 and Rett
syndrome. Lejeune Foundation (Paris, France) and Fondazione Umberto Vero-
nesi (Milan, Italy) provided additional funding to FBedo. AIRC (Associazione
Italiana per la Ricerca sul Cancro; Grant no. IG2016-ID18575) and ERC (Euro-
pean Research Council, Consolidator Grant no. 617978) provided additional
funding to MP. Compagnia di San Paolo Torino (9344), Ministero della Salute
Ricerca Finalizzata (GR-2016-02363972), and EU Era-Net Neuron 2017 "Snare-
opathies" provided additional funding to FBen. The team of the microscopy
facility at the San Raffaele Hospital (ALEMBIC) produced all the imaging data
described in this study. We thank the facility of Mouse Behavior studies at the
San Raffaele Hospital for supplying the equipment required for the behavior
tests. We thank Dr. Marzia Indrigo for her contributions in both behavioral
and molecular assessments.
Author contributions
LS, FB, and NL conceived the study and produced the manuscript. LS, GDR, GD,
CCG, MC, FM, DP, MDS, and PC produced experimental data. MP, FB, and FC
contributed to the interpretation of parts of the results.
Conflict of interest





Abuhatzira L, Makedonski K, Kaufman Y, Razin A, Shemer R (2007)
MeCP2 deficiency in the brain decreases BDNF levels by REST/CoREST-
mediated repression and increases TRKB production. Epigenetics 2:
214 – 222
Amir RE, Van den Veyver IB, Wan M, Tran CQ, Francke U, Zoghbi HY (1999)
Rett syndrome is caused by mutations in X-linked MECP2, encoding
methyl-CpG-binding protein 2. Nat Genet 23: 185 – 188
Armstrong DD (2001) Rett syndrome neuropathology review 2000. Brain
Develop 1: 572 – 576
Baj G, Patrizio A, Montalbano A, Sciancalepore M, Tongiorgi E (2014)
Developmental and maintenance defects in Rett syndrome neurons
identified by a new mouse staging system in vitro. Front Cell Neurosci 8:
1 – 15
Banerjee A, Miller MT, Li K, Sur M, Kaufmann WE (2019) Towards a better
diagnosis and treatment of Rett syndrome: a model synaptic disorder.
Brain 142: 239 – 248
Bedogni F, Cobolli Gigli C, Pozzi D, Rossi RL, Scaramuzza L, Rossetti G, Pagani
M, Kilstrup-Nielsen C, Matteoli M, Landsberger N (2016) Defects during
Mecp2 null embryonic cortex development precede the onset of overt
neurological symptoms. Cereb Cortex 26: 2517 – 2529
Bedogni F, Rossi RL, Galli F, Cobolli Gigli C, Gandaglia A, Kilstrup-Nielsen C,
Landsberger N (2014) Rett syndrome and the urge of novel approaches to
study MeCP2 functions and mechanisms of action. Neurosci Biobehav Rev
46: 187 – 201
Belichenko PV, Wright EE, Belichenko NP, Masliah E, Li HH, Mobley WC,
Francke U (2009) Widespread changes in dendritic and axonal
morphology in Mecp2-mutant mouse models of Rett syndrome:
evidence for disruption of neuronal networks. J Comp Neurol 514:
240 – 258
Ben-Ari Y (2002) Excitatory actions of gaba during development: the nature
of the nurture. Nat Rev Neurosci 3: 728 – 739
Ben-Ari Y, Gaiarsa J-L, Tyzio R, Khazipov R (2007) GABA: a pioneer transmitter
that excites immature neurons and generates primitive oscillations.
Physiol Rev 87: 1215 – 1284
Benowitz LI, Routtenberg A (1997) GAP-43: an intrinsic determinant of
neuronal development and plasticity. Trends Neurosci 20: 84 – 91
Berry-Kravis EM, Lindemann L, Jønch AE, Apostol G, Bear MF, Carpenter RL,
Crawley JN, Curie A, Des Portes V, Hossain F et al (2018) Drug
The paper explained
Problem
MECP2 mutations generate a number of neurological conditions
among which the most frequent is Rett syndrome (RTT). While RTT
signs become overt after an apparently asymptomatic phase, early
developmental defects have been detected, but their contribution to
the pathogenesis of RTT is still not understood. The description of
such early events could elucidate the pathogenesis of RTT and help
the proposition of new therapies, as only supportive strategies are
currently available for RTT patients.
Results
We show that the lack of Mecp2 reduces the ability of neurons to
respond to stimuli and alters their transcription and morphology. In
normal conditions, neuronal activity drives transcriptional and
morphological changes that support, in a feed-forward cycle, matura-
tion. We thus enhanced activity through the administration of the
Ampakine CX546 in cellular and animal models of RTT. Our data show
the effectiveness of this strategy, which proves more efficient if
applied during early stages of maturation, when brain circuits are
more prone to plasticity changes.
Impact
By showing the rescue effects produced by enhancing activity during
early stages of maturation, we highlight the contribution of defective
mechanisms of development to the phenotypes typically displayed by
RTT models. Our data show that Ampakine administration during
early development produces beneficial effects that persist long after
the end of the treatment.
ª 2021 The Authors EMBO Molecular Medicine 13: e12433 | 2021 15 of 18
Linda Scaramuzza et al EMBO Molecular Medicine
development for neurodevelopmental disorders: lessons learned from
fragile X syndrome. Nat Rev Drug Discov 17: 280 – 298
Bittolo T, Raminelli CA, Deiana C, Baj G, Vaghi V, Ferrazzo S, Bernareggi A,
Tongiorgi E (2016) Pharmacological treatment with mirtazapine rescues
cortical atrophy and respiratory deficits in MeCP2 null mice. Sci Rep 6:
19796
Bonetti C, Surace EM (2010) Mouse embryonic retina delivers information
controlling cortical neurogenesis. PLoS One 5: 6 – 11
Carlessi L, Fusar Poli E, De Filippis L, Delia D (2013) ATM-deficient human
neural stem cells as an in vitro model system to study neurodegeneration.
DNA Repair 12: 605 – 611
Carter JC, Lanham DC, Pham D, Bibat G, Naidu S, Kaufmann WE (2008)
Selective cerebral volume reduction in Rett syndrome: a multiple-
approach MR imaging study. Am J Neuroradiol 29: 436 – 441
Chahrour M, Zoghbi HY (2007) The story of Rett syndrome: from clinic to
neurobiology. Neuron 56: 422 – 437
Chao HT, Zoghbi HY, Rosenmund C (2007) MeCP2 controls excitatory
synaptic strength by regulating glutamatergic synapse number. Neuron 56:
58 – 65
Chen RZ, Akbarian S, Tudor M, Jaenisch R (2001) Deficiency of methyl-CpG
binding protein-2 in CNS neurons results in a Rett-like phenotype in mice.
Nat Genet 27: 327 – 331
Cheval H, Guy J, Merusi C, De Sousa D, Selfridge J, Bird A (2012) Postnatal
inactivation reveals enhanced requirement for MeCP2 at distinct age
windows. Hum Mol Genet 21: 3806 – 3814
Chiacchiaretta M, Latifi S, Bramini M, Fadda M, Fassio A, Benfenati F, Cesca F
(2017) Neuronal hyperactivity causes Na+/H+ exchanger-induced
extracellular acidification at active synapses. J Cell Sci 130: 1435 – 1449
Chiappalone M, Novellino A, Vajda I, Vato A, Martinoia S, van Pelt J (2005)
Burst detection algorithms for the analysis of spatio-temporal patterns in
cortical networks of neurons. Neurocomputing 65–66: 653 – 662
Cobolli Gigli C, Scaramuzza L, Gandaglia A, Bellini E, Gabaglio M, Parolaro
D, Kilstrup-Nielsen C, Landsberger N, Bedogni F (2016) MeCP2 related
studies benefit from the use of CD1 as genetic background. PLoS One
11: 1 – 14
Cobolli Gigli C, Scaramuzza L, De Simone M, Rossi RL, Pozzi D, Pagani M,
Landsberger N, Bedogni F (2018) Lack of methyl-CpG binding protein 2
(MeCP2) affects cell fate refinement during embryonic cortical
development. Cereb Cortex 28: 1846 – 1856
Corlew R, Bosma MM, Moody WJ (2004) Spontaneous, synchronous electrical
activity in neonatal mouse cortical neurons. J Physiol 560: 377 – 390
Corradini I, Focchi E, Rasile M, Morini R, Desiato G, Tomasoni R, Lizier M,
Ghirardini E, Fesce R, Morone D et al (2018) Maternal immune activation
delays excitatory-to-inhibitory gamma-aminobutyric acid switch in
offspring. Biol Psychiatry 83: 680 – 691
Cosentino L, Vigli D, Franchi F, Laviola G, De Filippis B (2019) Rett syndrome
before regression: a time window of overlooked opportunities for
diagnosis and intervention. Neurosci Biobehav Rev 107: 115 – 135
Dani VS, Chang Q, Maffei A, Turrigiano GG, Jaenisch R, Nelson SB (2005)
Reduced cortical activity due to a shift in the balance between excitation
and inhibition in a mouse model of Rett Syndrome. Proc Natl Acad Sci USA
102: 12560 – 12565
Dani VS, Nelson SB (2009) Intact long-term potentiation but reduced
connectivity between neocortical layer 5 pyramidal neurons in a mouse
model of Rett syndrome. J Neurosci 29: 11263 – 11270
Degano AL, Park MJ, Penati J, Li Q, Ronnett GV (2014) MeCP2 is required for
activity-dependent refinement of olfactory circuits. Mol Cell Neurosci 59:
63 – 75
D’haene B, Mestdagh P, Hellemans J, Vandesompele J (2012) miRNA
expression profiling: from reference genes to global mean normalization.
Methods Mol Biol 822: 261 – 272
Dolce A, Ben-Zeev B, Naidu S, Kossoff EH (2013) Rett syndrome and epilepsy:
an update for child neurologists. Pediatr Neurol 48: 337 – 345
Durand S, Patrizi A, Quast KB, Hachigian L, Pavlyuk R, Saxena A, Carninci P,
Hensch TK, Fagiolini M (2012) NMDA receptor regulation prevents
regression of visual cortical function in the absence of Mecp2. Neuron 76:
1078 – 1090
Fehr S, Bebbington A, Ellaway C, Rowe P, Leonard H, Downs J (2011) Altered
attainment of developmental milestones influences the age of diagnosis
of rett syndrome. J Child Neurol 26: 980 – 987
Flavell SW, Greenberg ME (2008) Signaling mechanisms linking neuronal
activity to gene expression and plasticity of the nervous system. Annu Rev
Neurosci 31: 563 – 590
Fukuda T, Itoh M, Ichikawa T, Washiyama K, Goto Y (2005) Delayed
maturation of neuronal architecture and synaptogenesis in cerebral cortex
of Mecp2-deficient mice. J Neuropathol Exp Neurol 64: 537 – 544
Gandaglia A, Brivio E, Carli S, Palmieri M, Bedogni F, Stefanelli G, Bergo A,
Leva B, Cattaneo C, Pizzamiglio L et al (2018) A novel Mecp2 Y120D
knock-in model displays similar behavioral traits but distinct molecular
features compared to the Mecp2-null mouse implying precision medicine
for the treatment of Rett syndrome. Mol Neurobiol 56: 4838 – 4854
Gorba T, Conti L (2013) Neural stem cells as tools for drug discovery: novel
platforms and approaches. Expert Opin Drug Discov 8: 1083 – 1094
Greer PL, Greenberg ME (2008) From synapse to nucleus: calcium-dependent
gene transcription in the control of synapse development and function.
Neuron 59: 846 – 860
Gritti A, Frölichsthal-Schoeller P, Galli R, Parati EA, Cova L, Pagano SF,
Bjornson CR, Vescovi AL (1999) Epidermal and fibroblast growth factors
behave as mitogenic regulators for a single multipotent stem cell-like
population from the subventricular region of the adult mouse forebrain. J
Neurosci 19: 3287 – 3297
de Groot MWGDM, Dingemans MML, Rus KH, de Groot A, Westerink RHS
(2014) Characterization of calcium responses and electrical activity in
differentiating mouse neural progenitor cells in vitro. Toxicol Sci 137:
428 – 435
Guy J, Gan J, Selfridge J, Cobb S, Bird A (2007) Reversal of neurological defects
in a mouse model of Rett syndrome. Science 315: 1143 – 1147
Guy J, Hendrich B, Holmes M, Martin JE, Bird A (2001) A mouse Mecp2-null
mutation causes neurological symptoms that mimic rett syndrome. Nat
Genet 27: 322 – 326
Hinz L, Torrella Barrufet J, Heine VM (2019) KCC2 expression levels are
reduced in post mortem brain tissue of Rett syndrome patients. Acta
Neuropathol Commun 7: 196
Horton AC, Yi JJ, Ehlers MD (2006) Cell type-specific dendritic polarity in the
absence of spatially organized external cues Brain. Cell Biol 35: 29 – 38
Ip JPK, Mellios N, Sur M (2018) Rett syndrome: insights into genetic,
molecular and circuit mechanisms. Nat Rev Neurosci 19: 368 – 382
Katz DM, Bird A, Coenraads M, Gray SJ, Menon DU, Philpot BD, Tarquinio DC
(2016) Rett syndrome: crossing the threshold to clinical translation. Trends
Neurosci 39: 100 – 113
Kishi N, Macklis JD (2004) MECP2 is progressively expressed in post-migratory
neurons and is involved in neuronal maturation rather than cell fate
decisions. Mol Cell Neurosci 27: 306 – 321
Korshunova I, Mosevitsky M (2010) Role of the growth-associated protein
GAP-43 in NCAM-mediated neurite outgrowth. Adv Exp Med Biol 663:
169 – 182
16 of 18 EMBO Molecular Medicine 13: e12433 | 2021 ª 2021 The Authors
EMBO Molecular Medicine Linda Scaramuzza et al
Kron M, Howell CJ, Adams IT, Ransbottom M, Christian D, Ogier M, Katz DM
(2012) Brain activity mapping in Mecp2 mutant mice reveals functional
deficits in forebrain circuits, including key nodes in the default mode
network, that are reversed with Ketamine treatment. J Neurosci 32:
13860 – 13872
Lagger S, Connelly JC, Schweikert G, Webb S, Selfridge J, Ramsahoye BH, Yu
M, He C, Sanguinetti G, Sowers LC et al (2017) MeCP2 recognizes cytosine
methylated tri-nucleotide and di-nucleotide sequences to tune
transcription in the mammalian brain. PLoS Genet 13: 1 – 26
Lauterborn JC, Truong GS, Baudry M, Bi X, Lynch G, Gall CM (2003) Chronic
elevation of brain-derived neurotrophic factor by Ampakines. J Pharmacol
Expermental Ther 307: 297 – 305
Li W, Bellot-Saez A, Phillips ML, Yang T, Longo FM, Pozzo-Miller L (2017) A
small-molecule TrkB ligand restores hippocampal synaptic plasticity and
object location memory in Rett syndrome mice. Dis Model Mech 10:
837 – 845
Lozovaya N, Nardou R, Tyzio R, Chiesa M, Pons-Bennaceur A, Eftekhari S, Bui
TT, Billon-Grand M, Rasero J, Bonifazi P et al (2019) Early alterations in a
mouse model of Rett syndrome: the GABA developmental shift is
abolished at birth. Sci Rep 9: 9276
Luhmann HJ, Fukuda A, Kilb W (2015) Control of cortical neuronal migration
by glutamate and GABA. Front Cell Neurosci 9: 4
Lynch G, Gall CM (2006) Ampakines and the threefold path to cognitive
enhancement. Trends Neurosci 29: 554 – 562
Magri L, Cambiaghi M, Cominelli M, Alfaro-Cervello C, Cursi M, Pala M,
Bulfone A, Garca-Verdugo JM, Leocani L, Minicucci F et al (2011) Sustained
activation of mTOR pathway in embryonic neural stem cells leads to
development of tuberous sclerosis complex-associated lesions. Cell Stem
Cell 9: 447 – 462
Marguet SL, Le-Schulte VTQ, Merseburg A, Neu A, Eichler R, Jakovcevski I,
Ivanov A, Hanganu-Opatz IL, Bernard C, Morellini F et al (2015) Treatment
during a vulnerable developmental period rescues a genetic epilepsy. Nat
Med 21: 1436 – 1444
Marın O (2016) Developmental timing and critical windows for the treatment
of psychiatric disorders. Nat Med 22: 1229 – 1238
Marschik PB, Kaufmann WE, Sigafoos J, Wolin T, Zhang D, Bartl-Pokorny KD,
Pini G, Zappella M, Tager-Flusberg H, Einspieler C et al (2013) Changing
the perspective on early development of Rett syndrome. Res Dev Disabil
34: 1236 – 1239
McGraw CM, Samaco RC, Zoghbi HY (2011) Adult neural function requires
MeCP2. Science 333: 186
Mellios N, Feldman DA, Sheridan SD, Ip JPK, Kwok S, Amoah SK, Rosen B,
Rodriguez BA, Crawford B, Swaminathan R et al (2018) MeCP2-regulated
miRNAs control early human neurogenesis through differential effects on
ERK and AKT signaling. Mol Psychiatry 23: 1051 – 1065
Menezes JR, Luskin MB (1994) Expression of neuron-specific tubulin defines a
novel population in the proliferative layers of the developing
telencephalon. J Neurosci 14: 5399 – 5416
Nagarajan N, Quast C, Boxall AR, Shahid M, Rosenmund C (2001) Mechanism
and impact of allosteric AMPA receptor modulation by the AmpakineTM
CX546. Neuropharmacology 41: 650 – 663
Nelson SB, Valakh V (2015) Excitatory/inhibitory balance and circuit
homeostasis in autism spectrum disorders. Neuron 87: 684 – 698
Nguyen MVC, Du F, Felice CA, Shan X, Nigam A, Mandel G, Robinson JK,
Ballas N (2012) MeCP2 is critical for maintaining mature neuronal
networks and global brain anatomy during late stages of postnatal
brain development and in the mature adult brain. J Neurosci 32:
10021 – 10034
Ogier M, Wang H, Hong E, Wang Q, Greenberg ME, Katz DM (2007) Brain-
derived neurotrophic factor expression and respiratory function improve
after Ampakine treatment in a mouse model of Rett syndrome. J Neurosci
27: 10912 – 10917
Paridaen JT, Huttner WB (2014) Neurogenesis during development of the
vertebrate central nervous system. EMBO Rep 15: 351 – 364
Patrizi A, Picard N, Simon AJ, Gunner G, Centofante E, Andrews NA, Fagiolini
M (2016) Chronic administration of the N-Methyl-D-Aspartate receptor
antagonist Ketamine improves Rett syndrome phenotype. Biol Psychiatry
79: 755 – 764
Picker JD, Yang R, Ricceri L, Berger-Sweeney J (2006) An altered neonatal
behavioral phenotype in Mecp2 mutant mice. NeuroReport 17: 541 – 544
Platel J-C, Boisseau S, Dupuis A, Brocard J, Poupard A, Savasta M, Villaz M,
Albrieux M (2005) Na+ channel-mediated Ca2+ entry leads to glutamate
secretion in mouse neocortical preplate. Proc Natl Acad Sci USA 102:
19174 – 19179
Renthal W, Boxer LD, Hrvatin S, Li E, Silberfeld A, Nagy MA, Griffith EC,
Vierbuchen T, Greenberg ME (2018) Characterization of human mosaic
Rett syndrome brain tissue by single-nucleus RNA sequencing. Nat
Neurosci 21: 1670 – 1679
Rietveld L, Stuss DP, McPhee D, Delaney KR (2015) Genotype-specific effects
of Mecp2 loss-of-function on morphology of layer V pyramidal neurons
in heterozygous female Rett syndrome model mice. Front Cell Neurosci
9: 145
Rosenberg SS, Spitzer NC (2011) Calcium signaling in neuronal development.
Cold Spring Harb Perspect Biol 3: a004259
Sampathkumar C, Wu YJ, Vadhvani M, Trimbuch T, Eickholt B, Rosenmund C
(2016) Loss of MeCP2 disrupts cell autonomous and autocrine BDNF
signaling in mouse glutamatergic neurons. Elife 5: 1 – 23
Sceniak MP, Lang M, Enomoto AC, Howell CJ, Hermes DJ, Katz DM (2016)
Mechanisms of functional hypoconnectivity in the medial prefrontal
cortex of Mecp2 null mice. Cereb Cortex 26: 1938 – 1956
Schitine C, Xapelli S, Agasse F, Sarda-Arroyo L, Silva AP, De Melo Reis RA, De
Mello FG, Malva JO (2012) Ampakine CX546 increases proliferation and
neuronal differentiation in subventricular zone stem/progenitor cell
cultures. Eur J Neurosci 35: 1672 – 1683
Shah RR, Bird AP (2017) MeCP2 mutations: progress towards understanding
and treating Rett syndrome. Genome Med 9: 7 – 10
Shepherd GMG, Katz DM (2011) Synaptic microcircuit dysfunction in genetic
models of neurodevelopmental disorders: focus on Mecp2 and Met. Curr
Opin Neurobiol 21: 827 – 833
Simmons DA, Rex CS, Palmer L, Pandyarajan V, Fedulov V, Gall CM, Lynch G
(2009) Up-regulating BDNF with an Ampakine rescues synaptic plasticity
and memory in Huntington’s disease knockin mice. Proc Natl Acad Sci USA
106: 4906 – 4911
Skene PJ, Illingworth RS, Webb S, Kerr ARW, James KD, Turner DJ, Andrews R,
Bird AP (2010) Neuronal MeCP2 is expressed at near histone-octamer
levels and globally alters the chromatin state. Mol Cell 37: 457 –468
Spitzer NC (2006) Electrical activity in early neuronal development. Nature
444: 707 – 712
Tang X, Drotar J, Li K, Clairmont CD, Brumm AS, Sullins AJ, Wu H, Liu XS,
Wang J, Gray NS et al (2019) Pharmacological enhancement of KCC2 gene
expression exerts therapeutic effects on human Rett syndrome neurons
and Mecp2 mutant mice. Sci Transl Med 11: eaau0164
Tang X, Kim J, Zhou L, Wengert E, Zhang L, Wu Z, Carromeu C, Muotri AR,
Marchetto MCN, Gage FH et al (2016) KCC2 rescues functional deficits in
human neurons derived from patients with Rett syndrome. Proc Natl Acad
Sci USA 113: 751 – 756
ª 2021 The Authors EMBO Molecular Medicine 13: e12433 | 2021 17 of 18
Linda Scaramuzza et al EMBO Molecular Medicine
Tischfield MA, Engle EC (2010) Distinct alpha- and beta-tubulin isotypes are
required for the positioning, differentiation and survival of neurons: new
support for the ’multi-tubulin’ hypothesis. Biosci Rep 30: 319 – 330
Tropea D, Giacometti E, Wilson NR, Beard C, McCurry C, Fu DD, Flannery
R, Jaenisch R, Sur M (2009) Partial reversal of Rett syndrome-like
symptoms in MeCP2 mutant mice. Proc Natl Acad Sci USA 106:
2029 – 2034
Walker TL, Yasuda T, Adams DJ, Bartlett PF (2007) The doublecortin-
expressing population in the developing and adult brain contains
multipotential precursors in addition to neuronal-lineage cells. J Neurosci
27: 3734 – 3742
Wang I-TJ, Reyes A-RS, Zhou Z (2013) Neuronal morphology in MeCP2 mouse
models is intrinsically variable and depends on age, cell type, and Mecp2
mutation. Neurobiol Dis 58: 3 – 12
Weissman TA, Riquelme PA, Ivic L, Flint AC, Kriegstein AR (2004) Calcium
waves propagate through radial glial cells and modulate proliferation in
the developing neocortex. Neuron 43: 647 – 661
Yamamoto N, Lopez-Bendito G (2012) Shaping brain connections through
spontaneous neural activity. Eur J Neurosci 35: 1595 – 1604
Zhang D, Bedogni F, Boterberg S, Camfield C, Camfield P, Charman T, Curfs L,
Einspieler C, Esposito G, De Filippis B et al (2019) Towards a consensus on
developmental regression. Neurosci Biobehav Rev 107: 3 – 5
License: This is an open access article under the
terms of the Creative Commons Attribution License,
which permits use, distribution and reproduction in
any medium, provided the original work is properly
cited.
18 of 18 EMBO Molecular Medicine 13: e12433 | 2021 ª 2021 The Authors
EMBO Molecular Medicine Linda Scaramuzza et al
